You are here

Home » Content

Valeriana officinalis kök ekstraktının antidepresan etkisinin zorlu yüzme testi ile değerlendirilmesi

Evaluating the antidepressant effect of Valeriana officinalis root extract with forced swim test

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2009
DOI: 
doi:10.2399/tahd.09.148

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: Herbs are used as a traditional treatment methods from ancient times, especially in Egypt, in Sumer and in China. One of these herbs is Valeriana officinalis used for its anxiolitic and gastrointestinal spasmolytic effects and as a sleep aid. This study was performed to investigate especially the antidepressant effect of valerian extract used for insomnia. Methods: Twenty male Sprague-Dawley rats were divided into two groups randomly and every morning one group took Valeriana officinalis root extract and the other took %5 dextrose solution. A forced swim test (Porsolt) was applied on the 11th and 12th days. Results: On the first day, the freeze duration of the valerian group was significantly shorter than the placebo group (42.4±27.1 and 145±91.3 second respectively) (p=0.00963). There was also statis-ticaly significant difference between the freeze duration of the first 5 minutes of the first and the second days between the two groups (F=8.941, p=0.009) and the two treatments (F=6.888, p=0.018). The first 5 minutes freeze duration of the valerian group in the first day was 3±3.92 seconds and 14±25.5 seconds in the second day, whereas in the placebo group it was 20.9±23.1 seconds in the first day and 44.9±32.1 seconds in the second day. Conclusions: The shorter freeze duration in valerian group in the first 5 minutes and in the total period of the first day show the existence of an anxiolytic effect. The fact that, the freeze duration of the valerian group was statisticaly shorter than the freeze duration of the placebo group, may indicate an antidepressant effect.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Bitkisel kaynaklı tedavi yöntemleri çok eski zamanlardan bu yana, -başta Mısır, Sümer ve Çin'de- kullanılmıştır. Bu bitkilerden biri, anksiyolitik, sindirim spazmlarını çözücü ve uykuya yardımcı olarak kullanılan Valeriana officinalis'tir. Bu çalışmanın ama¬cı uykusuzlukta kullanılan valerian ekstraktının antidepresan etki taşıyıp taşımadığının araştırılmasıdır. Yöntem: Sprague-Dawley cinsi 20 erkek sıçan rastgele iki gruba ayrılarak, bir gruba, her sabah, Valeriana officinalis kök ekstraktı, diğer gruba ise %5 dekstroz eriyiği verildi. 11. ve 12. gün zorlu yüzme testi (Porsolt) uygulandı. Bulgular: 1. günde, valerian kök ekstraktı alan grubun hareketsiz kalma (donma) süresi plasebo grubundan anlamlı derecede kısa bulundu (sırasıyla 42.4±27.1 ve 145+91.3 saniye) (p=0.00963). 1. ve 2. günün ilk 5 dakikaları kıyaslandığında grupların (F=8.941, p=0.009) ve tedavilerin (F=6.888, p=0.018) donma süreleri istatistiksel olarak anlamlı derecede farklı idi. Valerian grubunun 1. gü¬nün ilk 5 dakikasındaki donma süresi 3±3.92 saniye, 2. günde ise 14±25.5 saniye iken, plasebo grubunda ilk gün 20.9±23.1 saniye, 2. gün ise 44.9±32.1 saniye idi. Sonuç: Valerian grubundaki donma süresinin, ilk 5 dakikada ve toplamda daha kısa olması, anksiyolitik etkiyi göstermektedir; va¬lerian grubundaki donma süresinin 2. gündeki artışının plasebo grubundan istatistiksel olarak anlamlı derecede kısa olması ise an-tidepresan etkinliğe işaret edebilir.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_13_pp_148-152.pdf
  • 3
148-152
  • Turkish

REFERENCES

References: 

1. Upton R. Valeriana officinalis. J Altern Complement Med 2001; 7: 15-7.
2. Monograph. Valeriana officinalis. Altern Med Rev 2004; 9: 438-41.
3. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 1999; 51: 505-12.
4. Hendriks H, Bos R, Allersman DP, Malingre TM, Koster AS. Pharmacological screening of valerenal and some other components of essential oil of Valeriana officinalis. Planta Med 1981; 42: 62-8.
5. Cavadas C, Araujo I, Cotrim MD ve ark. In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABA receptor in rat brain. Arzneimittelforschung 1995; 45: 753-5.
6. Ortiz JG, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [3H] flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H] GABA release. Neurochem Res 1999; 24: 1373-8.
7. Riedel E, Hansel R, Ehrke G. Inhibition of gamma-aminobutyric acid catabolism by valerenic acid derivatives. Planta Med 1982; 46: 219-20.
8. Bodesheim U, Holzl J. Isolation and receptor binding properties of alka¬loids and lignans from Valeriana officialis L. Pharmazie 1997; 52: 386-91.
9. Hadley S, Petry J. Valerian. Am Fam Physician 2003; 67: 1755-8.
10. Evenden JL, Ryan RC, Mattila ME. Behavioural testing of antidepres-sants: a practical pre-clinical approach to clinical problems. Behavioral Neuroscience: a practical approach'da. Ed. Sahgal A. Oxford: Oxford University Press, 1993; 55-91.
11. Andreatini R, Sartori VA, Seabre ML, Leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res2002; 16: 650-4.
12. Cropley M, Cave Z, Ellis J, Middleton RW. Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytother Res2002; 16: 23-7.
13. Tang JY, Zeng YS, Chen QG, Qin YJ, Chen SJ, Zhong ZQ. Effects of Valerian on the level of 5-hydroxytryptamine, cell proliferation and neu¬rons in cerebral hippocampus of rats with depression induced by chronic mild stress. Zhong Xi Yi Jie He Xue Bao 2008; 6: 283-8.
14. Bunney WE. Jr, Davis JM. Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry1965; 13: 483-94.
15. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry1965; 122: 509-22.
16. Lapin IP, Oxenkrug GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969;
1: 132-6.
17. Asberg M, Bertlsson L, Mârtensson B, Scalia-Tomba GP, Thoren P, Trâskman-Bendz L. CSF monoamine metabolites in melancholia. Acta
Psychiatr Scand1984; 69: 201-19.
18. Gerner RH, Fairbanks L, Anderson GM ve ark. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of nor¬mal controls. Am J Psychiatry 1984; 141: 1533-40.

Thank you for copying data from http://www.arastirmax.com